{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T12:06:32Z","timestamp":1792325192211,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00277-025-06646-x","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T04:12:24Z","timestamp":1759810344000},"page":"4565-4575","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical profile and treatment outcomes in paediatric and adult acute promyelocytic leukemia: experience from a tertiary care centre in Northern India"],"prefix":"10.1007","volume":"104","author":[{"given":"Harshal","family":"Mamlekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandhini","family":"Gangadaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Kashyap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaliqur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Vijayaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prisha","family":"Nankana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"6646_CR1","doi-asserted-by":"publisher","unstructured":"Stanley M, McKenna RW, Ellinger G, Brunning RD (1985) Classification of 358 Cases of Acute Myeloid Leukemia by FAB Criteria: Analysis of Clinical and Morphologic Features. In: Bloomfield CD, editor. Chronic and Acute Leukemias in Adults [Internet]. Boston, MA: Springer US; [cited 2025 May 3]. pp. 147\u201374. (McGuire WL, editor. Cancer Treatment and Research; vol. 26). Available from: http:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/978-1-4613-2581-9_5","DOI":"10.1007\/978-1-4613-2581-9_5"},{"key":"6646_CR2","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1182\/blood-2010-03-276196","volume":"116","author":"F Lo-Coco","year":"2010","unstructured":"Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A et al (2010) Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA group. Blood 116:3171\u20133179","journal-title":"Blood"},{"key":"6646_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.leukres.2004.04.021","volume":"29","author":"MS Tallman","year":"2005","unstructured":"Tallman MS, Brenner B, Serna JDL, Dombret H, Falanga A, Kwaan HC et al (2005) Meeting report. Leuk Res 29:347\u2013351","journal-title":"Leuk Res"},{"key":"6646_CR4","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1182\/blood-2007-07-100669","volume":"111","author":"J De La Serna","year":"2008","unstructured":"De La Serna J, Montesinos P, Vellenga E, Ray\u00f3n C, Parody R, Le\u00f3n A et al (2008) Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 111:3395\u20133402","journal-title":"Blood"},{"key":"6646_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.0954-6820.1957.tb00124.x","volume":"159","author":"LK Hillestad","year":"1957","unstructured":"Hillestad LK (1957) Acute promyelocytic leukemia. Acta Med Scand 159:189\u2013194","journal-title":"Acta Med Scand"},{"key":"6646_CR6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.11622\/smedj.2014105","volume":"55","author":"F Karim","year":"2014","unstructured":"Karim F, Shaikh U, Adil SN, Khurshid M (2014) Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centre. Singap Med J 55:443\u2013447","journal-title":"Singap Med J"},{"key":"6646_CR7","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00280-019-03825-2","volume":"83","author":"S Adige","year":"2019","unstructured":"Adige S, Lapidus RG, Carter-Cooper BA, Duffy A, Patzke C, Law JY et al (2019) Equipotent doses of Daunorubicin and Idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation. Cancer Chemother Pharmacol 83:1105\u20131112","journal-title":"Cancer Chemother Pharmacol"},{"key":"6646_CR8","first-page":"1247","volume":"96","author":"MA Sanz","year":"2000","unstructured":"Sanz MA, Lo Coco F, Mart\u00edn G, Avvisati G, Ray\u00f3n C, Barbui T et al (2000) Definition of relapse risk and role of Nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96:1247\u20131253","journal-title":"Blood"},{"key":"6646_CR9","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1111\/jth.15048","volume":"18","author":"L Franco","year":"2020","unstructured":"Franco L, Becattini C, Beyer-Westendorf J, Vanni S, Nitti C, Re R et al (2020) Definition of major bleeding: prognostic classification. J Thromb Haemost 18:2852\u20132860","journal-title":"J Thromb Haemost"},{"key":"6646_CR10","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","volume":"113","author":"P Montesinos","year":"2009","unstructured":"Montesinos P, Bergua JM, Vellenga E, Ray\u00f3n C, Parody R, De La Serna J et al (2009) Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 113:775\u2013783","journal-title":"Blood"},{"key":"6646_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/236174","volume":"2012","author":"Y Ipek","year":"2012","unstructured":"Ipek Y, Hulya D, Melih A (2012) Disseminated exfoliative dermatitis associated with all-transretinoic acid in the treatment of acute promyelocytic leukemia. Case Rep Med 2012:1\u20133","journal-title":"Case Rep Med"},{"key":"6646_CR12","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","volume":"111","author":"ZY Wang","year":"2008","unstructured":"Wang ZY, Chen Z (2008) Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111:2505\u20132515","journal-title":"Blood"},{"key":"6646_CR13","doi-asserted-by":"publisher","first-page":"316","DOI":"10.4103\/0019-509X.84938","volume":"48","author":"J Bajpai","year":"2011","unstructured":"Bajpai J, Sharma A, Kumar L, Dabkara D, Raina V, Kochupillai V et al (2011) Acute promyelocytic leukemia: an experience from a tertiary care centre in North India. Indian J Cancer 48:316","journal-title":"Indian J Cancer"},{"key":"6646_CR14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.4103\/0019-509X.176731","volume":"52","author":"A Dayama","year":"2015","unstructured":"Dayama A, Dass J, Seth T, Mahapatra M, Mishra P, Saxena R (2015) Clinico-hematological profile and outcome of acute promyelocytic leukemia patients at a tertiary care center in north India. Indian J Cancer 52:309","journal-title":"Indian J Cancer"},{"key":"6646_CR15","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.1016\/j.clml.2019.12.011","volume":"20","author":"RP Yedla","year":"2020","unstructured":"Yedla RP, Bala SC, Pydi VR, Kuruva SP, Chennamaneni R, Konatam ML et al (2020) Outcomes in adult acute promyelocytic leukemia: A decade experience. Clin Lymphoma Myeloma Leuk 20:e158\u2013e164","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6646_CR16","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.3324\/haematol.2018.198614","volume":"103","author":"L Ad\u00e8s","year":"2018","unstructured":"Ad\u00e8s L, Thomas X, Bresler AG, Raffoux E, Spertini O, Vey N et al (2018) Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group. Haematologica 103:2033\u20132039","journal-title":"Haematologica"},{"key":"6646_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.blre.2014.09.013","volume":"29","author":"L Zhang","year":"2015","unstructured":"Zhang L, Samad A, Pombo-de-Oliveira MS, Scelo G, Smith MT, Feusner J et al (2015) Global characteristics of childhood acute promyelocytic leukemia. Blood Rev 29:101\u2013125","journal-title":"Blood Rev"},{"key":"6646_CR18","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1182\/blood-2002-02-0632","volume":"100","author":"MS Tallman","year":"2002","unstructured":"Tallman MS (2002) All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American intergroup protocol. Blood 100:4298\u20134302","journal-title":"Blood"},{"key":"6646_CR19","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3324\/haematol.10874","volume":"92","author":"RH Jacomo","year":"2007","unstructured":"Jacomo RH, Melo RAM, Souto FR, De Mattos ER, De Oliveira CT, Fagundes EM et al (2007) Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica 92:1431\u20131432","journal-title":"Haematologica"},{"key":"6646_CR20","doi-asserted-by":"publisher","first-page":"3866","DOI":"10.1200\/JCO.2010.28.5031","volume":"28","author":"V Mathews","year":"2010","unstructured":"Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P et al (2010) Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. JCO 28:3866\u20133871","journal-title":"JCO"},{"key":"6646_CR21","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1182\/blood-2010-02-269621","volume":"116","author":"BL Powell","year":"2010","unstructured":"Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM et al (2010) Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American leukemia intergroup study C9710. Blood 116:3751\u20133757","journal-title":"Blood"},{"key":"6646_CR22","unstructured":"Sherin PM Clinical profile and induction outcome in adult and pediatric acute promyelocytic leukemia"},{"key":"6646_CR23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s12288-018-1051-9","volume":"35","author":"S Jacob","year":"2019","unstructured":"Jacob S, Jacob SE, Suryanarayana BS, Dutta TK (2019) Clinical profile and short term outcome of adult patients with acute myeloid leukemia. Indian J Hematol Blood Transfus 35:431\u2013436","journal-title":"Indian J Hematol Blood Transfus"},{"key":"6646_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.07.027","volume":"34","author":"S Serefhanoglu","year":"2010","unstructured":"Serefhanoglu S, Buyukasik Y, Goker H, Sayinalp N, Haznedaroglu IC, Aksu S et al (2010) Clinical features and outcomes of 49 Turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy. Leuk Res 34:e317\u2013e319","journal-title":"Leuk Res"},{"key":"6646_CR25","first-page":"11","volume":"7","author":"S Conneely","year":"2020","unstructured":"Conneely S, Stevens A (2020) Advances in pediatric acute promyelocytic leukemia. Children (Basel) 7:11","journal-title":"Children (Basel)"},{"key":"6646_CR26","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/sj.leu.2402899","volume":"17","author":"C Girmenia","year":"2003","unstructured":"Girmenia C, Lo Coco F, Breccia M, Latagliata R, Spadea A, D\u2019Andrea M et al (2003) Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen. Leukemia 17:925\u2013930","journal-title":"Leukemia"},{"key":"6646_CR27","first-page":"1014","volume":"90","author":"F Mandelli","year":"1997","unstructured":"Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C et al (1997) Molecular remission in PML\/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and Idarubicin (AIDA) therapy. Gruppo Italiano-Malattie ematologiche Maligne dell\u2019adulto and associazione Italiana Di ematologia ed oncologia pediatrica cooperative groups. Blood 90:1014\u20131021","journal-title":"Blood"},{"key":"6646_CR28","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1182\/blood.V118.21.942.942","volume":"118","author":"JK Altman","year":"2011","unstructured":"Altman JK, Rademaker A, Cull E, Weitner BB, Ofran Y, Rosenblat TL et al (2011) Administration of all-Trans retinoic acid (ATRA) to newly diagnosed patients (pts) with acute promyelocytic leukemia (APL) is delayed even at experienced centers and associated with an increased early death rate (EDR): a retrospective analysis of 205 Pts. Blood 118:942\u2013942","journal-title":"Blood"},{"key":"6646_CR29","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1080\/10428194.2019.1613540","volume":"60","author":"M Stahl","year":"2019","unstructured":"Stahl M, Tallman MS (2019) Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all. Leuk Lymphoma 60:3107\u20133115","journal-title":"Leuk Lymphoma"},{"key":"6646_CR30","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.clml.2015.11.018","volume":"16","author":"CC Coombs","year":"2016","unstructured":"Coombs CC, DeAngelis LM, Feusner JH, Rowe JM, Tallman MS (2016) Pseudotumor cerebri in acute promyelocytic leukemia patients on intergroup protocol 0129: clinical description and recommendations for new diagnostic criteria. Clin Lymphoma Myeloma Leuk 16:146\u2013151","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6646_CR31","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12011-023-03676-2","volume":"202","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Zhang S, Zhang F, Zhang Q, Wei H, Xiu R et al (2024) Clinical indicators of hepatotoxicity in newly diagnosed acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Biol Trace Elem Res 202:122\u2013132","journal-title":"Biol Trace Elem Res"},{"key":"6646_CR32","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1182\/blood-2008-05-159632","volume":"112","author":"MA Sanz","year":"2008","unstructured":"Sanz MA, Montesinos P, Vellenga E, Ray\u00f3n C, De La Serna J, Parody R et al (2008) Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA group. Blood 112:3130\u20133134","journal-title":"Blood"},{"key":"6646_CR33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cancergen.2018.12.003","volume":"231\u2013232","author":"SM Baba","year":"2019","unstructured":"Baba SM, Shah ZA, Pandith AA, Dil-Afroze null, Jan A, Mir KA et al (2019) Influence of bcr-3 PML-RAR\u03b1 transcript on outcome in acute promyelocytic leukemia patients of Kashmir treated with all-trans retinoic acid and\/or arsenic tri-oxide. Cancer Genet 231\u2013232:14\u201321","journal-title":"Cancer Genet"},{"key":"6646_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1062524","volume":"12","author":"SG Iyer","year":"2023","unstructured":"Iyer SG, Elias L, Stanchina M, Watts J (2023) The treatment of acute promyelocytic leukemia in 2023: paradigm, advances, and future directions. Front Oncol 12:1062524","journal-title":"Front Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06646-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06646-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06646-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:30:48Z","timestamp":1761283848000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06646-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6646"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06646-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6794583\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"1 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the Institutional Ethics Committee (Sanjay Gandhi Post graduate institute of medical sciences, Lucknow, India).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}